Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Taiwan Liposome Forms China Commercialization JV with Jixi Biotech

publication date: Jan 22, 2018

Taiwan Liposome will form a joint venture with Jixi Biotechnology to market Taiwan Liposome's products in China. JiXi will make an investment of "millions of dollars" in a Hong Kong subsidiary of Taiwan Liposome in exchange for a minority stake in the company. Taiwan Liposome said it would use Jixi Biotech's experience and resources in mainland China to promote and sell their drugs more efficiently. More details....

Stock Symbol: (TT: 4152)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China